Metformin and breast cancer: Basic knowledge in clinical context

United Kingdom Diabetes study group, 1995, United Kingdom Prospective Diabetes Study (UKPDS). Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years, BMJ, 31, 83 Diamanti-Kandarakis, 2010, Metformin in polycystic ovary syndrome, Ann N Y Acad Sci, 1205, 192, 10.1111/j.1749-6632.2010.05679.x Bianchi, 2007, Treating the metabolic syndrome, Exp Rev Cardiovasc Ther, 5, 491, 10.1586/14779072.5.3.491 Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512 Noto, 2012, Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis, PLoS ONE, 7, e33411, 10.1371/journal.pone.0033411 Col, 2012, Metformin and breast cancer risk: a meta-analysis and critical literature review, Breast Cancer Res Treat, 135, 639, 10.1007/s10549-012-2170-x Bonanni, 2012, Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial, J Clin Oncol, 30, 2593, 10.1200/JCO.2011.39.3769 Niraula, 2012, Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study, Breast Cancer Res Treat, 135, 821, 10.1007/s10549-012-2223-1 Hadad, 2011, Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial, Breast Cancer Res Treat, 128, 783, 10.1007/s10549-011-1612-1 Cazzaniga, 2013, The effect of metformin on apoptosis in a breast cancer presurgical trial, Br J Cancer, 109, 2792, 10.1038/bjc.2013.657 Campagnoli, 2013, Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer, Clin Breast Cancer, 13, 433, 10.1016/j.clbc.2013.08.012 Wahdan-Alaswad, 2013, Glucose promotes breast cancer aggression and reduces metformin efficacy, Cell Cycle, 12, 3759, 10.4161/cc.26641 Hadad, 2014, Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle, Clin Transl Oncol, 16, 746, 10.1007/s12094-013-1144-8 Zordoky, 2014, The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention, Biochim Biophys Acta, 1840, 1943, 10.1016/j.bbagen.2014.01.023 Hirsch, 2013, Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth, Proc Natl Acad Sci USA, 110, 972, 10.1073/pnas.1221055110 Lega, 2014, The effect of metformin on mortality following cancer among patients with diabetes, Cancer Epidemiol Biomarkers Prev, 23, 1974, 10.1158/1055-9965.EPI-14-0327 https://clinicaltrials.gov/ct2/show/NCT01905046?term=metformin&recr=Open&cond=breast+cancer&intr=metformin&age=1&phase=12&rank=5, last accessed in November 2014 https://clinicaltrials.gov/, last accessed in November 2014.18 Dowling, 2011, Understanding the benefit of metformin use in cancer treatment, BMC Med, 9, 33, 10.1186/1741-7015-9-33 O’Reilly, 2006, MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925 Easton, 2006, IRS-1: auditing the effectiveness of mTOR inhibitors, Cancer Cell, 9, 153, 10.1016/j.ccr.2006.02.027 Goodwin, 2011, Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents, Breast Cancer Res Treat, 126, 215, 10.1007/s10549-010-1224-1 Dowling, 2012, Metformin in cancer: translational challenges, J Mol Endocrinol, 48, R31, 10.1530/JME-12-0007 Weber, 2012, Deconvoluting mTOR biology, Cell Cycle, 236, 10.4161/cc.11.2.19022 DeCensi, 2014, Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial, Breast Cancer Res Treat, 148, 81, 10.1007/s10549-014-3141-1 Vici, 2014, Triple positive breast cancer: A distinct subtype, Cancer Treat Rev Vici, 2014, Outcomes of HER-2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study, Breast Cancer Res Treat, 147, 599, 10.1007/s10549-014-3133-1 Inwald, 2013, Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry, Breast Cancer Res Treat, 139, 539, 10.1007/s10549-013-2560-8 Luporsi, 2012, Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat, 132, 895, 10.1007/s10549-011-1837-z Taneja, 2010, Classical and novel prognostic markers for breast cancer and their clinical significance, Clin Med Insights Oncol, 20, 15 Lu, 2002, Live or let die: the cell’s response to p53, Nat Rev Cancer, 2, 594, 10.1038/nrc864 Dobes, 2014, Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients, Oncol Rep, 32, 1695, 10.3892/or.2014.3346 Olivier, 2006, The clinical value of somatic TP53 mutations in 1794 patients with breast cancer, Clin Cancer Res, 12, 117, 10.1158/1078-0432.CCR-05-1029 Kruse, 2009, Modes of p53 regulation, Cell, 137, 609, 10.1016/j.cell.2009.04.050 Zajkowicz, 2011, The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases, Mech Ageing Dev, 132, 543, 10.1016/j.mad.2011.09.002 Shackelford, 2009, The LKB1-AMPK pathway: metabolism and growth control in tumour suppression, Nat Rev Cancer, 9, 563, 10.1038/nrc2676 Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016 Nieminen, 2013, Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis, Proc Natl Acad Sci USA, 110, 10.1073/pnas.1208530110 Sen, 2012, p53 and metabolism: old player in a new game, Transcription, 3, 119, 10.4161/trns.20094 Barba, 2012, Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort, Ann Oncol, 23, 1838, 10.1093/annonc/mdr540 Vici, 2014, P53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER-2 positive patients treated with trastuzumab, Oncotarget, 5, 10382, 10.18632/oncotarget.2060